Cartesian Therapeutics (RNAC) announced that updated efficacy and safety data from the Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis will be presented at the 2nd Annual Cell Therapy for Autoimmune Disease Summit, being held December 2-4, 2024 in Philadelphia. Presentation Title: Perspectives on Bringing Cell Therapies to the Autoimmune Space: From Concept to Clinic
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics Reports Q3 2024 Financial Results
- Cartesian Therapeutics announces employment inducement grant
- Cartesian Therapeutics price target lowered to $41 from $45 at H.C. Wainwright
- Cartesian Therapeutics reports Q3 EPS ($1.13) , consensus (79c)
- Cartesian announces Phase 2b trial of Descartes-08 achieved primary endpoint